This article is more than 5 years old. Information may no longer be current.
Janssen launches mobile app for IBD patients, physicians
Click Here to Manage Email Alerts
Janssen Biotech has announced the launch of Gut Check, a new platform including a mobile app for patients and a dashboard for health care providers designed to improve inflammatory bowel disease monitoring.
“Managing IBD is a significant challenge, and improving the efficiency and timeliness of communication between patients and healthcare professionals is critical in providing optimal care,” Andrew Greenspan, MD, vice president of medical affairs at Janssen Biotech, said in the press release. “We created Gut Check to enable real-time communication between health care professionals and patients, with the ultimate goal of enabling [health care professionals] to more closely monitor disease progression.”
The mobile app uses biweekly NIH-validated patient-reported outcome surveys to allow patients to track their daily symptoms and lifestyle habits for real-time sharing with their health care providers and also features long-term progress tracking. Health care providers can view, filter and compare internal, local and national patient data through a HIPAA-compliant dashboard on a tablet or computer.
The mobile app for patients also includes a GPS-enabled bathroom finder, social media integration and other features.
“From my experience, people living with IBD often under-report their symptoms — they tend to focus on how they have been feeling the past few days versus the past few months,” Ralph McKibbin, MD, a gastroenterologist at Blair Gastroenterology Associates in Altoona, Pa., said in a press release. “Early intervention is key when it comes to caring for IBD. New platforms like Gut Check will help me to more closely monitor my patients in real-time.”
The app is free for IBD patients, and the dashboard is free for healthcare professionals, both of which are available in the Apple App Store and Google Play.
Disclosures: Greenspan reports he is an employee of Janssen. Healio Gastroenterology could not confirm McKibbin’s relevant financial disclosures at the time of publication.